Ironwood Pharmaceuticals (IRWD): prezzo delle azioni e notizie

Simboli Simboli	Prezzo	Cambio	% di cambio	Tendenza	Chiusura prec.	Apri	Alto	Basso	Volume	Cap. mercato
SIXB Materials SIXB Materials	SIXB +0,25%	1.104,10	+2,73	+0,25%	—	1.101,37	1.103,63	1.105,31	1.091,41	—	—
SIXC Communications SIXC Communications	SIXC -1,50%	604,16	-9,19	-1,50%	—	613,35	613,35	613,35	601,49	—	—
SIXE Energy SIXE Energy	SIXE -0,09%	1.197,81	-1,02	-0,09%	—	1.198,83	1.199,68	1.199,75	1.182,41	—	—
SIXI Industrials SIXI Industrials	SIXI -0,88%	1.740,41	-15,54	-0,88%	—	1.755,95	1.754,06	1.756,03	1.734,69	—	—
SIXM Financials SIXM Financials	SIXM -0,64%	634,44	-4,07	-0,64%	—	638,51	637,41	637,41	633,05	—	—
SIXR Staples SIXR Staples	SIXR -0,31%	840,90	-2,62	-0,31%	—	843,52	843,35	846,40	837,93	—	—
SIXRE Real estate SIXRE Real estate	SIXRE -0,38%	215,13	-0,82	-0,38%	—	215,95	215,95	216,84	215,06	—	—
SIXT Technology SIXT Technology	SIXT +2,86%	3.228,71	+89,80	+2,86%	—	3.138,91	3.189,30	3.230,85	3.174,76	—	—
SIXU Utilities SIXU Utilities	SIXU +0,16%	935,87	+1,50	+0,16%	—	934,37	934,72	938,26	927,50	—	—
SIXV Health care SIXV Health care	SIXV -1,37%	1.457,12	-20,31	-1,37%	—	1.477,43	1.474,12	1.474,12	1.451,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,83%	2.399,84	+19,65	+0,83%	—	2.380,19	2.389,34	2.403,04	2.380,47	—	—

IRWD:NASDAQ

Ironwood Pharmaceuticals

3,93 USD

+3,69%

(+0,14) 1G

3,90 USD

-0,76% (-0,030)

After Hours

Chiuso: 24 apr, 16:00:01 GMT-4 · USD

Tutti i simboli

YTD

MAX

	Simbolo	Prezzo	Cambio	% di cambio

Generazione degli approfondimenti principali per IRWD in corso…

Apri

3,79 USD

Alto

3,93 USD

Basso

3,72 USD

Cap. mercato

640,82 Mln

Vol. medio

2,61 Mln

Volume

1,32 Mln

Rapporto P/E

26,67

Max 52 sett.

5,78 USD

Min 52 sett.

0,53 USD

Utili per azione

0,15 USD

Beta

0,17

Azioni in circolazione

163,06 Mln

N. di dipendenti

100

Azioni correlate

BCRX

BioCryst Pharmaceuticals

8,94 USD

+2,05%

BNAI

Brand Engagement Network Inc

30,02 USD

-4,09%

CTMX

CytomX Therapeutics Inc

4,40 USD

-1,12%

RLAY

Relay Therapeutics Inc

15,13 USD

+0,27%

Articoli giornalistici

Da fonti sul web

Yahoo Finance

2 giorni fa

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Profilo

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia

Informazioni su Ironwood Pharmaceuticals

CEO-

Dipendenti100

Data di fondazione1998

SedeBoston, Massachusetts, Stati Uniti

Settore-

Sito webironwoodpharma.com

Tutti i valori in USD	mar 2025	giu 2025	set 2025	dic 2025
Fatturato	41,14 Mln	85,24 Mln	122,06 Mln	47,71 Mln
Costo dei beni venduti	27,43 Mln	23,37 Mln	22,47 Mln	21,86 Mln
Costo del venduto	27,43 Mln	23,37 Mln	22,47 Mln	21,86 Mln
Spese di ricerca e sviluppo	-	-	-	-
Spese totali per ricerca e sviluppo	-	-	-	-
Spese di vendita, generali e amministrative	24,26 Mln	16,80 Mln	21,91 Mln	19,29 Mln
Spese operative	24,26 Mln	16,80 Mln	21,91 Mln	19,29 Mln
Spese operative totali	51,69 Mln	40,17 Mln	44,38 Mln	41,16 Mln
Reddito operativo	-10,55 Mln	45,07 Mln	77,68 Mln	6,55 Mln
Altri redditi non operativi	37,00K	39,00K	40,00K	77,00K
EBT inclusi elementi straordinari	-36,27 Mln	37,82 Mln	68,02 Mln	455,00K
EBT esclusi elementi straordinari	-17,71 Mln	37,57 Mln	70,22 Mln	203,00K
Spese per imposte sul reddito	1,11 Mln	14,22 Mln	27,94 Mln	2,73 Mln
Aliquota fiscale effettiva	-3,07%	37,60%	41,08%	600,22%
Altre spese operative	-	-	-	-
Risultato netto	-37,39 Mln	23,60 Mln	40,08 Mln	-2,28 Mln
Margine di profitto netto	-90,87%	27,69%	32,84%	-4,77%
Utili per azione	-0,14	0,14	0,24	-0,01
Interessi e reddito da investimento	869,00K	818,00K	930,00K	1,46 Mln
Interesse passivo	-8,07 Mln	-8,36 Mln	-8,43 Mln	-7,89 Mln
Interessi passivi netti	-7,20 Mln	-7,54 Mln	-7,50 Mln	-6,43 Mln
Addebiti per ammortamento e svalutazione	-	-	-	-
EBITDA	-10,07 Mln	45,54 Mln	78,16 Mln	7,01 Mln
Utile o perdita derivante dalla vendita di asset	-	85,00K	7,00K	-3,00K

I contenuti creati con l'AI potrebbero contenere errori. Scopri di più

AssistenzaInvia feedbackPrivacy Termini Disclaimer

Google Finanza

Ricerca